Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: Drug repurposing. (January 2020)

• Record Type: Journal Article
• Authors: Mishra, Ritu; Krishan, Shri; Siddiqui, Ali Nasir; Kapur, Prem; Khayyam, Khalid Umer; Sharma, Manju
• Is Part Of: Tuberculosis. Volume 120(2020)
• Publication Date: 2020-01
• Subjects: Antitubercular therapy -- Adjuvant drugs -- Drug repurposing -- Mycobacterium tuberculosis -- Tuberculosis; 616.995
• DOI: 10.1016/j.tube.2020.101902
• Languages: English
• ISSNs: 1472-9792

Abstract

Abstract: Despite the availability of potent antitubercular drugs, tuberculosis (TB) still remains one of the world's leading causes of death. The current antitubercular therapy (ATT) suffers from a drawback of longer duration that imposes a major challenge of patient non compliance and resistance development. The current scenario necessitates alternative strategies with potential to shorten treatment duration that could pave the way for improved clinical outcomes. In recent years, host directed adjunctive therapies have raised considerable attention and emerged as a promising intervention which targets clinically relevant biological pathways in hosts to modulate pathological immune responses. Few of the approved drugs namely statins, metformin, ibuprofen, aspirin, valproic acid, adalimumab, bevacizumab, zileuton and vitamin D3 have shown promising results in clinical outcomes during their preliminary screening in TB patients and can be potentially repurposed as antitubercular drugs. This review highlights clinical and non clinical evidences of some already existing drug and their targets in hosts that could help in shortening treatment duration and reducing bacterial burden at minimal doses.